UCB7858

Phase 2Small molecule

UCB

UCB7858 is one of 44 small molecule programs targeting Focal Segmental Glomerulosclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal Segmental GlomerulosclerosisActive, not recruiting

Focal Segmental GlomerulosclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

51 competitors in Focal Segmental Glomerulosclerosis

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Glucophage

Empaveli

Apellis Pharmaceuticals

Approved

—4

Accutane

CConrado Roberto Hoffmann Filho

Rituxan

3 6

Avapro

Sanofi

Phase 3

2 7

Filspari

TTravere Therapeutics, Inc.

Phase 3

1 8

Cyclosporin

AstraZeneca

Phase 3

1 9

Simulect

Novartis

Phase 2

1 10

Cellcept

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

Completed· UCB logo

UCB·Phase 1·NCT02879877·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for UCB7858. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UCB7858 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UCB7858. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UCB

UCB7858

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Ascending Dose1 trial

References

Drug Info

Quick Facts

Related News